Trial
NCT04610658
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Bristol-Myers Squibb; Jazz Pharmaceuticals
Condition
Small-cell Lung Cancer
Intervention
Nivolumab
Why stopped
DLTs
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-02